J&J Hopes To Win Back Prestige Case After Judge Favors Home Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's LifeScan subsidiary plans to appeal a June 21 ruling by a Delaware district court that Home Diagnostics Inc.' s Prestige blood glucose test system does not infringe J&J patents.
You may also be interested in...
Home Diagnostics, Inc. v. J&J Lifescan
U.S. Court of Appeals for the Federal Circuit in Washington, D.C. rules that Home Diagnostics' Prestige glucose monitor did not infringe on patents held by Johnson & Johnson subsidiary Lifescan. April 6 decision upholds earlier finding by U.S. District Court in Wilmington, Delaware. Home Diagnostics pulled the Prestige product from the market in November 1999 and has since introduced the Prestige LX, which uses a significantly different technology from the earlier version, the firm says (1"The Gray Sheet" July 3, 2000, p. 17)
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.